LONDON--(BUSINESS WIRE)--Just three of 2007's top companies producing cancer medicines are forecast to significantly grow their sales in the oncology segment over the next five years, says a new market research report from URCH Publishing.
Of these top ten companies, only Roche, Genentech and Merck are tipped to grow sales of their cancer portfolio by double-digit annual growth rates says,
"Cancer Market Trends 2008 - 2012: Key market forecasts and growth opportunities".
In contrast, Sanofi-Aventis, AstraZeneca and J&J are forecast to suffer declining cancer sales over the next five years.
.../...Other changes will include Genentech passing Novartis to become the third leading cancer company, while Merck will overtake Eli Lilly, Pfizer, AstraZeneca and Sanofi-Aventis to become the sixth leading cancer company in 2012.
.../...
Only five of the top 10 cancer products in 2007 are forecast to increase sales over the next five years, notes the report.
Amgen's Aranesp and Epogen, J&J's Eprex/Procrit and Sanofi-Aventis' Taxotere and Eloxatin are all forecast to suffer declining sales between 2007 and 2012.
Entradas
No hay comentarios:
Publicar un comentario